治疗高血压药物B244的Ⅱ期临床试验完成患者入选工作
发布时间：2018-08-05 14:17
【摘要】：正AOBiome公司完成其领先候选药B244治疗高血压的Ⅱ期临床试验的患者入选工作。该试验是随机、双盲、安慰剂对照研究,入选116名收缩期高血压患者,主终点是4周治疗后,给药组与赋形剂对照,平均降低收缩期高血压的初步效果和安全性。先前的Ⅰ/Ⅱa期临床试验显示,B244治疗寻常性痤疮者无严重副作
[Abstract]:AOBiome was selected to complete a phase II clinical trial of its leading candidate drug B244 for the treatment of hypertension. The trial was a randomized, double-blind, placebo controlled trial. 116 patients with systolic hypertension were enrolled in the study. The primary effect and safety of systolic hypertension were reduced on average in the administration group and excipient group after 4 weeks of treatment. Previous stage 鈪，
本文编号：2166045
[Abstract]:AOBiome was selected to complete a phase II clinical trial of its leading candidate drug B244 for the treatment of hypertension. The trial was a randomized, double-blind, placebo controlled trial. 116 patients with systolic hypertension were enrolled in the study. The primary effect and safety of systolic hypertension were reduced on average in the administration group and excipient group after 4 weeks of treatment. Previous stage 鈪，
本文编号：2166045
本文链接：https://www.wllwen.com/yixuelunwen/yiyaoxuelunwen/2166045.html
最近更新
教材专著
